| abstract |
The present invention relates to a novel receptor binding domain variant with reduced ACE2 binding capacity, a fusion protein comprising same, and a use thereof. The present invention can overcome the disadvantage of existing vaccines using a spike protein of coronavirus or a receptor binding domain thereof, the disadvantage being that the decrease in the expression of ACE2 by binding to ACE2 may cause side effects in the lungs or the heart, and in particular, may be fatal for patients suffering from underlying diseases of the lungs or heart. In particular, the fusion protein combining a receptor binding domain and Fc of the present invention has greatly improved in vivo half-life, and is highly likely to be used as a multivalent immunogenic composition having superior efficacy by binding an N protein, an M protein, an ORF protein, etc. of SARS-CoV-2 through additional modification. Accordingly, the receptor binding domain variant of the present invention is useful for the prevention and treatment of coronavirus infections including SARS-CoV-2. |